Delcath Systems Inc
Veridion Score
Composite trend over time
Why is DCTH moving today?
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for DCTH.
DCTH insider activity
Delcath Systems Inc
No multi-insider buying cluster in the last 90 days
Net buying: $287K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-06 | 2026-03-06 | Pennell Sandra | Insider | buy | $9.04 | 5,533 | 77,018 | $50K | SEC Form 4 |
| 2026-03-03 | 2026-03-02 | MICHEL GERARD J | Insider | buy | $8.96 | 11,200 | 342,034 | $100K | SEC Form 4 |
| 2025-11-25 | 2025-11-21 | Sylvester John Richard | Insider | buy | $8.89 | 4,386 | 14,936 | $39K | SEC Form 4 |
| 2025-11-13 | 2025-11-11 | MICHEL GERARD J | Insider | buy | $8.53 | 11,500 | 330,834 | $98K | SEC Form 4 |
DCTH contract awards, year to date.
Public federal awards linked to this ticker.
DCTH lobbying filings, year to date.
Registered lobbying filings matched to Delcath Systems Inc.